Publications by authors named "E S Debus"
Article Synopsis
- - The study focused on the use of endovenous laser ablation (EVLA) to treat recurrent varicose veins after small saphenous vein (SSV) surgery, analyzing its feasibility and initial results in 40 patients.
- - Out of 45 EVLA procedures, there was a 97.8% immediate technical success rate, but 13.3% of limbs experienced further issues requiring additional treatment within a median follow-up period of 77 days.
- - The majority of patients had complex vein anatomy, but no significant complications arose that required further medical intervention, demonstrating that EVLA is a promising option for managing recurrent varicose veins.
Background: Marfan syndrome (MFS) guidelines recommend optimal pharmacologic therapy (OPT) and replacement of the ascending aorta (RAA) at 5.0 cm in diameter to prevent acute type A aortic dissection (ATAAD) and death. The effect of early MFS diagnosis and initiation of therapy on outcomes is not known.
View Article and Find Full Text PDFInternational publication activity in orthopaedic surgery over a ten-year interval.
Eur J Trauma Emerg Surg
December 2024
Purpose: International English language publication activities in orthopaedic surgery comparing the years 2008/09 to 2018/19 were analyzed.
Methods: 20 international journals listed on PubMed were examined. The impact factor (IF) for each journal was determined using the InCites Journal Citation Report.
Article Synopsis
- The VOYAGER PAD study found that rivaroxaban 2.5 mg combined with aspirin reduced cardiovascular events but increased bleeding in patients with symptomatic peripheral artery disease (PAD) after revascularization.
- The study specifically looked at fragile patients, defined by age, weight, and kidney function, and assessed the drug's efficacy and safety for this group.
- Results showed fragile patients were at greater risk for ischemic events and bleeding, but the effectiveness of rivaroxaban was consistent across both fragile and nonfragile patients.
Objective: To assess the characteristics and clinical outcomes of patients with lower extremity peripheral artery disease (PAD) in XATOA receiving dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin according to lower extremity revascularisation (LER) history.
Methods: XATOA is an international, multicentre, prospective, single arm registry study.